{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-070839","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.057072+00:00","generated_at":"2026-06-04T13:28:09.247745+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Enliven Therapeutics raises $90M in PIPE, extends cash runway into late 2026","bullets":["Gross proceeds ~$90M from sale of 5.36M shares at $14.00 and pre-funded warrants at $13.999.","PIPE priced at ~11% premium to March 18 close; expected to close March 21, 2024.","Proceeds plus existing cash expected to fund operations into late 2026 and through key clinical milestones.","ELVN-001 Phase 1a proof-of-concept data to be presented at KOL event on April 11, 2024.","ELVN-002 combination trial first patient dosing expected in Q2 2024; Phase 1 data in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-070839","json":"https://secwatch.observer/filing/0001193125-24-070839.json","markdown":"https://secwatch.observer/filing/0001193125-24-070839.md","text":"https://secwatch.observer/filing/0001193125-24-070839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312524070839/0001193125-24-070839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312524070839/d759882d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:28:09.247745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51f6054afcf99e64b59f317c674ba99e70abb048","claim":"Enliven Therapeutics, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $90 million (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, Enliven Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 5,357,144 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at $14.00 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants\") to purchase 1,071,505 shares of Common Stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312524070839/0001193125-24-070839-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein"},{"label":"Value","value":"approximately $90 million"},{"label":"Effective","value":"2024-03-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}